Full Breakdown
Trump Administration Reclassifies Medical Marijuana: A Major Policy Shift
4/24/2026, 3:07:37 AM
Historic Reclassification of Medical Marijuana
On April 23, 2026, Acting Attorney General Todd Blanche signed an order reclassifying state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. This change marks a significant shift in U.S. drug policy, as Schedule I drugs, which include heroin and LSD, are classified as having no accepted medical use and a high potential for abuse. In contrast, Schedule III drugs, such as ketamine and testosterone, are recognized for their medical applications and have a moderate to low potential for physical and psychological dependence.
The reclassification does not legalize marijuana for medical or recreational use at the federal level, but it alters the regulatory landscape for medical marijuana operators. The order allows these operators to deduct business expenses on federal taxes for the first time and facilitates a more streamlined registration process with the Drug Enforcement Administration (DEA). Blanche stated, “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.”
Background and Context
The push for reclassification began under President Joe Biden's administration, which initiated a review of marijuana's classification in 2022. Following this, the Department of Health and Human Services recommended a change, leading to President Trump's December 2025 executive order directing the reclassification process. Despite the federal ban on marijuana, 40 states have legalized its medical use, and 24 states, along with the District of Columbia, have legalized it for recreational use.
Implications of the Reclassification
The reclassification is expected to ease barriers for research on cannabis and improve access to medical treatments. Blanche emphasized that the Department of Justice is “delivering on President Trump’s promise to expand Americans’ access to medical treatment options.” However, critics argue that the change is largely symbolic. Morgan Fox of the National Organization for the Reform of Marijuana Laws (NORML) stated, “Moving it out of that classification allows us to have policy conversations that don't start and end with that definition,” while advocating for full federal legalization.
Criticism and Opposition
Opponents of the reclassification, including Kevin Sabet, CEO of Smart Approaches to Marijuana, expressed concerns that the move sends a confusing message about marijuana's risks. Sabet criticized the administration for what he termed a pro-drug stance, suggesting that there are better ways to enhance marijuana research without providing tax breaks to cannabis companies.
What's Next?
The Trump administration plans to hold a hearing on June 29, 2026, to consider broader reclassification of marijuana. This step could further reshape the regulatory framework surrounding cannabis, although the timeline for any additional changes remains uncertain.
Verbatim Quotes
- “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.” — Todd Blanche, Acting Attorney General
- “Moving it out of that classification allows us to have policy conversations that don't start and end with that definition,” — Morgan Fox, National Organization for the Reform of Marijuana Laws
- “With this move, we are now confronted with the most pro-drug administration in our history,” — Kevin Sabet, Smart Approaches to Marijuana
The reclassification of medical marijuana represents a pivotal moment in U.S. drug policy, reflecting changing attitudes toward cannabis while maintaining federal restrictions.
